Validation of a Protein-to-Creatinine (Pr/Cr) Strip Test for Proteinuria Screening in Low-Resource Settings

Organization Location: 
Seattle, Washington

The World Health Organization estimates that preeclampsia/eclampsia (PE/E) accounts for at least 16% of maternal deaths in low-resource settings (LRS).  The risk that a woman in a low-resource country will die of PE/E is approximately 300 times greater than that for a woman in a high-resource setting (HRS), mainly because a great number of pregnant women do not have easy access to adequate health care in LRS; many live in rural areas, do not have transportation or time to travel for health care, and, once PE begins, the progression to eclampsia can happen so quickly that women cannot get the care they need. Our team, in collaboration with LifeAssay Diagnostics (Pty) Ltd (Cape Town, South Africa), has developed a low-cost, accurate, easy-to-use protein to creatinine (Pr/Cr) strip test for evaluating and monitoring proteinuria. A Saving Lives at Birth (SLAB) validation award would enable larger-scale clinical validation through a special opportunity to enroll the Pr/Cr strip test as part of an ongoing clinical trial starting in 2016. Successful validation would be cornerstone evidence for replacement of the commonly used protein-only dipstick with the Pr/Cr strip test and thereby potentially expand the use of a more accurate proteinuria test to a higher number of pregnant women who don’t have access to centralized medical facilities.

See video